The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

Teva Pharmaceutical is a victim of its own success, Chief Executive Richard Francis said Wednesday as Teva stock plummeted on its light earnings outlook. For the year, the pharma behemoth expects ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Teva CEO Richard Francis said, "2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products and key innovative products.

Teva Pharmaceuticals' CEO advocates for quicker FDA generic drug approvals, which he argues would save the U.S. healthcare system money. Concurrently, the Trump administration has revised the number ...

Teva’s CEO Richard Francis, who’s been leading the company’s turnaround since his arrival in early 2023, helped provide some color on the guidance during a conference call with analysts.

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing sales forecast for tardive dyskinesia (TD) drug Ingrezza commanded much of t | ...

The current health news highlights Abridge raising $250 million to boost AI medical documentation, layoffs involving ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has opened the reporting season for Israeli companies by publishing its fourth quarter and full year 2024 financial results.